Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Central China Normal University currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single active matter is being reviewed by 1 distinct examiner, which centralizes the university's interactions with the patent office. The prosecution is also confined to 1 distinct art unit, indicating that the technology being patented fits within a specific and specialized technical category. This focused structure allows for a very direct and efficient prosecution process. Prosecution in this area often faces rigorous scrutiny regarding enablement and written description, making the choice of art unit particularly significant.
The busiest examiner for this portfolio is STANKOVIC, BRATISLAV, who is currently overseeing the 1 pending office action. With only a distinct examiner involved, the entire outcome of the university's current active filings depends on the review of this single individual. This 1 to 1 relationship between the examiner and the pending workload simplifies the management of the case. The specific requirements of the 1 distinct art unit will be the primary focus for the applicant as they work to resolve the 1 pending office action. This concentrated arrangement allows for a targeted approach to addressing the office's concerns.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STANKOVIC, BRATISLAV | 1 | 70.0% | +21.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19101888 | HSL PROTEIN, GENE, VECTOR, CELL, COMPOSITION AND USE THEREOF, AND METHOD FOR IMPROVING HERBICIDE RESISTANCE OF CROPS | STANKOVIC, BRATISLAV | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19101888 | HSL PROTEIN, GENE, VECTOR, CELL, COMPOSITION AND USE THEREOF, AND METHOD FOR IMPROVING HERBICIDE RESISTANCE OF CROPS | STANKOVIC, BRATISLAV | — |
| Art Unit | Apps |
|---|---|
| 1662 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19101888 | HSL PROTEIN, GENE, VECTOR, CELL, COMPOSITION AND USE THEREOF, AND METHOD FOR IMPROVING HERBICIDE RESISTANCE OF CROPS | STANKOVIC, BRATISLAV | 1662 | §101§102 | Non-Final OA | — | Pending | Feb 06, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCentral China Normal University has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Bratislav Stankovic has the most, with 1 of Central China Normal University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
